Bluebird Bio Inc (BLUE)

[stocksrising]

Newsletter view hits the main driver of Future gains from Lenti study: “ The SCD patient population tends to have a higher overall risk of developing cancers, especially those involving the blood such as AML. There is a ‘CHANCE’ that the patient developed AML independent of the treatment, which would be a best-case scenario for investors. That said, the company has mentioned that the LentiGlobin vector was present in the AML cells, so further investigation is needed”.